INTSINTENSITY THERAPEUTICS, INC.
Mkt Cap
$13.09MVolume
570.19M52W High
$3.4052W Low
$0.1853PE Ratio
-0.32INTS Fundamentals
Price
$0.7173Prev Close
$0.2669Open
$0.771550D MA
$0.2684Beta
0.00Avg. Volume
3.03MEPS (Annual)
-$1.17P/B
3.20Rev/Employee
$0.00Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal Intensity...
PR Newswire·3h ago
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') Following Periodic Review Drug Monitoring Committee...
PR Newswire·9mo ago
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead...
PR Newswire·10mo ago
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the...
PR Newswire·11mo ago
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct...
PR Newswire·11mo ago
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') in a Late-Breaking Session at the 2024...
PR Newswire·1y ago
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR...
PR Newswire·1y ago
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial...
PR Newswire·1y ago
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR...
PR Newswire·1y ago
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update...
PR Newswire·1y ago